Our History

Targovax is a clinical stage immuno-oncology company born out of the merger in July 2015 of Targovax and Oncos Therapeutics. It is dedicated to the development of highly targeted immunotherapy treatments for cancer patients.

Key Historical Developments

2017

  • Moves share listing to Oslo Børs.
  • Announced encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients.
  • Appointment of Erik Digman Wiklund as new CFO

2016

  • Promising one-year overall survival interim data and immune activation data for TGO1 in pancreatic cancer
  • ONCOS-102 Phase l/ll clinical trial in mesothelioma started
  • IPO at the Oslo stock market (Oslo Axess)
  • Appointment of Øystein Soug as new CEO

2015

  • Completed recruitment of patients for the clinical trial CT TG01-01 investigating TG01 in operable pancreatic cancer
  • Pre-clinical testing of TG02 completed
  • TG02 for clinical Phase I/II produced
  • Appointment of Øystein Soug as new CFO and Peter Skorpil as Head of Business Development
  • Presentation of interim data from CT-TG01-01 and ONCOS-102 at ASCO 2015
  • Completion of Targovax merger with Oncos
  • Successful completion of a NOK 200 million private placement
  • Ludwig Cancer Research and Cancer Research Institute partner with Targovax to test ONCOS-102 in early-phase clinical trials
  • Targovax and the biotech company SOTIO a.s. partner to combine ONCOS-102 and SOTIO's dendritic cell therapy DCVAC/PCa for the treatment of advanced prostate cancer

2014

  • OTC listed at Oslo Stock Exchange
  • Phase I part of Phase I/II clinical trial of TG01 successfully completed
  • Phase II part of Phase I/II clinical trial of TG01 initiated
  • Phase I clinical trial for ONCOS-102 completed
  • Appointment of Gunnar Gardemyr as CEO of Targovax and Magnus Jaderberg as CMO of Oncos

2013

  • First patient treated for TGO1 in combination with gemcitabine

2012

  • Clinical trial initiated for TGO1 Phase I/II in operable pancreatic cancer
  • First patient enrolled in Phase I clinical trial for ONCOS-102, an adenovirus 5/3 with a GM-CSF transgene
  • Secured IND for ONCOS-102

2011

  • Orphan drug designation granted in EU and US for TG01
  • GMP production established for TGO1

2010

  • Targovax founded on the basis of the history from Norsk Hydro by inventors of the RAS-targeted technology and The Radium Hospital Research Foundation
  • Healthcap makes its initial investment in Oncos

2009

  • Oncos Therapeutics ("Oncos") founded

2007

  • First administration of ONCOS-102

1998

  • First patient treated with TG01 (Norsk Hydro)

1993

  • First patient (ever) treated with RAS peptide